Skip to main content
. 2020 Feb 14;19(4):239–252. doi: 10.1038/s41573-019-0056-x

Table 1.

Current licensed vaccines in the United States and Europe

Region Vaccine technology/platform Vaccine type Vaccine name (manufacturer) Target/MOA Adjuvant used
United States Inactivated virus Split virus Afluria (Seqirus) HAI None
Fluarix (GSK) HAI None
FluLavel (GSK) HAI None
Fluzone, Fluzone HD (Sanofi Pasteur) HAI None
Fluad (Seqirus) HAI None
Subunit Fluvirin (CLS Limited) HAI None
Flucelvax (Novartis) HAI None
Live-attenuated Live, cold-adapted FluMist (AstraZeneca) HAI None
Recombinant protein Non-purified HA FluBlok (Sanofi Pasteur) HAI None
Europe Inactivated virus Split virus Influvac, Imuvac (Abbot) HAI None
Fluarix, Alpharix, Influsplit (GSK) HAI None
3Fluart (Omninvest) HAI Alum
Afluria, Enzira (Pfizer/CSL) HAI None
Vaxigrip, Vaxigrip Tetra (Sanofi Pasteur) HAI None
Subunit Agrippal (Seqirus) HAI None
Fluad (Seqirus) HAI MF59
Live-attenuated Live, cold-adapted Fluenz Tetra (AstraZeneca) HAI None

HA, haemagglutinin; HAI, haemagglutination inhibition; HD, high-dose; MOA; mode of action. Sources: European Centre for Disease Prevention and Control: seasonal influenza vaccines, CDC: United States influenza vaccines 2019–2020.